Literature DB >> 6987764

Compliance with ocular therapy.

F S Ashburn, I Goldberg, M A Kass.   

Abstract

Patient noncompliance with the physician's prescribed therapeutic regimen can present serious obstacles both to individual patient care and to the obtaining of information necessary for controlled drug trials. Unfortunately, the physician often is unable to determine whether and to what extent a patient is not complying with therapy. This article reviews the problem of patient noncompliance with particular emphasis on how and why noncompliance occurs, and methods of predicting, detecting and coping with the defaulting patient.

Entities:  

Mesh:

Year:  1980        PMID: 6987764     DOI: 10.1016/0039-6257(80)90045-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  14 in total

1.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

2.  Compliance and knowledge about glaucoma in patients at tertiary glaucoma units.

Authors:  Kaweh Mansouri; Milko E Iliev; Kaspar Rohrer; Tarek Shaarawy
Journal:  Int Ophthalmol       Date:  2011-10-07       Impact factor: 2.031

3.  Importance of asking about glaucoma.

Authors:  N C Price
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

4.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

5.  Noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study.

Authors:  Myoung Hee Park; Kyu-Dong Kang; Jungil Moon
Journal:  Jpn J Ophthalmol       Date:  2012-10-12       Impact factor: 2.447

6.  Drug attitude and adherence to anti-glaucoma medication.

Authors:  Samin Hong; Sung Yong Kang; Jong Uk Yoon; Uicheon Kang; Gong Je Seong; Chan Yun Kim
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

7.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

8.  First-year treatment costs among new initiators of topical prostaglandin analogs.

Authors:  Jordana K Schmier; David W Covert; Alan L Robin
Journal:  Clin Ophthalmol       Date:  2009-11-16

9.  Hybrid Electrospun Polycaprolactone Mats Consisting of Nanofibers and Microbeads for Extended Release of Dexamethasone.

Authors:  Kuan-Hui Hsu; Sheng-Po Fang; Chang-Lin Lin; Yan-Shin Liao; Yong-Kyu Yoon; Anuj Chauhan
Journal:  Pharm Res       Date:  2016-03-14       Impact factor: 4.200

10.  The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.